

Live more comfortably  
with bone cancer. It is possible.



## BIOCERA-VET OSTEOSARCOMA RTU, READY-TO-USE HIGHLY INJECTABLE CALCIUM-PHOSPHATE BONE SUBSTITUTE FOR CEMENTOPLASTY



# OSTEOSARCOMA RTU

- ▶ Improves quality of life & relieves pain
- ▶ Reduces risk of pathologic fracture
- ▶ Minimally-invasive
- ▶ Rapid recovery
- ▶ Cost-effective

NEW  
IN OSTEOSARCOMA  
MANAGEMENT

### INDICATIONS

- ▶ Cementoplasty for palliative care of canine and feline osteosarcoma
- ▶ Large bone gaps filling

### BIOCERA-VET OSTEOSARCOMA RTU

- ▶ 1 or 2 pre-filled 12 cc syringes
- ▶ Delivering device
- ▶ Luer-Lock injection cannula

OSTEOSARCOMA RTU  
1 x 12cc - 2 x 12cc



TheraVet® is a vet company headquartered in Belgium. Its mission is to develop innovative, safe and effective treatments to improve the well-being and quality of life of companion animals suffering from osteoarticular diseases. It is listed on Euronext Growth® Brussels and Paris.

More info at:  
[www.bioceravet.com](http://www.bioceravet.com)  
[customerservice@thera.vet](mailto:customerservice@thera.vet)




## OSTEOSARCOMA, A SAD DIAGNOSIS FOR PETS, PET OWNERS AND VETS

Osteosarcoma is the most common bone cancer in dogs. When left untreated, the average survival time of a dog with osteosarcoma is usually no more than 4-5 months. Amputation of the primary tumor remains the mainstay of treatment. However, it is not always feasible due to the weight of the dog, the presence of other pathologies and/or the owner's refusal. Other treatment options are potentially more invasive, expensive and not always effective.

## CEMENTOPLASTY WITH BIOCERA-VET OSTEOSARCOMA PROVIDES A PALLIATIVE SOLUTION, IMPROVING THE QUALITY OF LIFE

BIOCERA-VET® OSTEOSARCOMA RTU is a ready-to-use highly injectable synthetic self-hardening calcium-phosphate bone substitute. When percutaneously injected into the bone that has been weakened by tumor, it offers the needed mechanical strength to reduce the risk of pathologic fractures, relieves the pain and improves the patient's comfort and quality of life.

The data recovered from a recent clinical study\* showed promising results for the use of BIOCERA-VET\*\* as a palliative solution for dogs with osteosarcoma.



Owner evaluation of: ■ Quality of Life (QoL)

Improved limb function, significant reduction of pain and better quality of life are the main benefits observed in the patients involved. The low rate of complications also indicates that BIOCERA-VET® is a safe alternative when faced with the challenging palliative approach of osteosarcoma.



**“The cementoplasty procedure with BIOCERA-VET® is an interesting alternative to amputation because it allows, through a low-traumatic surgical procedure, an improvement in the animal's welfare, an improvement in lameness and significant pain relief”**

*DVM O. Gauthier  
Professor of Veterinary Surgery at College of  
Veterinary Medicine ONIRIS Nantes, France*


**DO YOU WANT TO KNOW MORE?  
Check out the testimonial!**



## BIOCERA-VET, NEW IN PALLIATIVE CARE OF CANINE OSTEOSARCOMA

**BIOCERA-VET OSTEOSARCOMA RTU is perfectly suited for cementoplasty:**

- Mechanical strength comparable to cancellous bone within 24 hours, and complete hardening within 96 hours
- Ease of injection and long workability
- Allows monitoring of percutaneous injection by fluoroscopy and the assessment of postoperative radiographs thanks to its radiopacity



Radiographic images of an osteosarcoma case at the proximal tibia, before (left) and after (right) a percutaneous cementoplasty\*\*\*. The bone substitute BIOCERA-VET fills the void caused by the bone tumor.

**Practical use of BIOCERA-VET OSTEOSARCOMA RTU:**

- Minimally invasive procedure
- Less post-operative care
- Reduced analgesic treatment after cementoplasty

(\*) BIOCERA-VET® OSTEOSARCOMA - Efficacy and safety assessment of BIOCERA-VET® cementoplasty in dogs with osteosarcoma May 2022. Collaborating veterinary surgeons: Pr Olivier Gauthier, ONIRIS, Ecole Nationale Vétérinaire, France; Dr Guillaume Ragetly, CHV Frégis, France; Dr Aurélie Klajer, Eiffelvet, France; Dr Bertrand Vedrine, Seinevet, France; Dr Julien Letesson, CV Lameilhé, France; Dr Julien Carabalona, Clinique Olliolis, France. Authors: Aquilino Villamonte, DVM, PhD, Veterinary Technical Manager and Céline Molle, PhD, Clinical Director (TheraVet®). Data-on-file is available on request at customerservice@thera.vet (\*\*) Clinical Study performed with BIOCERA-VET® OSTEOSARCOMA 8cc (\*\*\*) Cementoplasty was performed with BIOCERA-VET® OSTEOSARCOMA 8cc

